|
Name |
2,6,10-Dodecatrienal, 3,7,11-trimethyl-, (Z,Z)-
|
Molecular Formula | C15H24O | |
IUPAC Name* |
(2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trienal
|
|
SMILES |
CC(=CCC/C(=C\CC/C(=C\C=O)/C)/C)C
|
|
InChI |
InChI=1S/C15H24O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11-12H,5-6,8,10H2,1-4H3/b14-9-,15-11-
|
|
InChIKey |
YHRUHBBTQZKMEX-FBXUGWQNSA-N
|
|
Synonyms |
(Z,Z)-Farnesal; Farnesal, (2Z,6Z)-; FEMA No. 4019, (2Z,6Z)-; 9Y09C480QU; 2,6,10-Dodecatrienal, 3,7,11-trimethyl-, (Z,Z)-; 2,6,10-Dodecatrienal, 3,7,11-trimethyl-, (2Z,6Z)-; 3790-68-9; UNII-9Y09C480QU; (2Z,6Z)-farnesal; SCHEMBL12189855; ZINC13507227; Q27273366
|
|
CAS | 3790-68-9 | |
PubChem CID | 21596343 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 220.35 | ALogp: | 4.9 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 17.1 | Aromatic Rings: | 0 |
Heavy Atoms: | 16 | QED Weighted: | 0.332 |
Caco-2 Permeability: | -4.374 | MDCK Permeability: | 0.00002250 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.016 | 20% Bioavailability (F20%): | 0.975 |
30% Bioavailability (F30%): | 0.911 |
Blood-Brain-Barrier Penetration (BBB): | 0.832 | Plasma Protein Binding (PPB): | 98.06% |
Volume Distribution (VD): | 3.181 | Fu: | 1.82% |
CYP1A2-inhibitor: | 0.873 | CYP1A2-substrate: | 0.471 |
CYP2C19-inhibitor: | 0.477 | CYP2C19-substrate: | 0.885 |
CYP2C9-inhibitor: | 0.245 | CYP2C9-substrate: | 0.827 |
CYP2D6-inhibitor: | 0.269 | CYP2D6-substrate: | 0.384 |
CYP3A4-inhibitor: | 0.122 | CYP3A4-substrate: | 0.239 |
Clearance (CL): | 8.089 | Half-life (T1/2): | 0.819 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.974 |
Drug-inuced Liver Injury (DILI): | 0.135 | AMES Toxicity: | 0.249 |
Rat Oral Acute Toxicity: | 0.888 | Maximum Recommended Daily Dose: | 0.243 |
Skin Sensitization: | 0.941 | Carcinogencity: | 0.82 |
Eye Corrosion: | 0.555 | Eye Irritation: | 0.96 |
Respiratory Toxicity: | 0.968 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001717 | 1.000 | D05XQE | 0.537 | ||||
ENC001467 | 0.702 | D09XWD | 0.521 | ||||
ENC001096 | 0.686 | D03VFL | 0.407 | ||||
ENC001434 | 0.674 | D0M1PQ | 0.278 | ||||
ENC001464 | 0.621 | D01ZUA | 0.207 | ||||
ENC001465 | 0.621 | D06BLQ | 0.205 | ||||
ENC001716 | 0.571 | D0S7WX | 0.176 | ||||
ENC001664 | 0.537 | D03ZFG | 0.176 | ||||
ENC001649 | 0.529 | D0X7XG | 0.174 | ||||
ENC000314 | 0.518 | D02DGU | 0.172 |